Re: Improved prediction of long-term, other cause mortality in men with prostate cancer: T. J. Daskivich, K. Chamie, L. Kwan, J. Labo, A. Dash, S. Greenfield and M. S. Litwin J Urol 2011; 186: 1868-1873

摘要

To the Editor: These authors from the University of California, Los Angeles reexamined the original Charlson comorbidity index and devised a novel prostate cancer specific comorbidity index using data from 1,598 patients diagnosed with prostate cancer at 2 Veterans Administration hospitals. Given the changing paradigm of management of prostate cancer in the prostate specific antigen era, the consideration of accurate comorbidity assessment becomes tremendously important for men evaluating the risks and benefits of treatment vs active surveillance. Using similar methodology relative to the original study by Charlson et al, the authors re-weighted common comorbidities and applied them to updated HRs, which allowed a more accurate identification of men at risk for nonprostate cancer related mortality. They should be congratulated for undertaking a highly relevant endeavor.